IPO registrations (S-1, F-1) · Registrants
NOMAD POWER SOLUTIONS, INC.
- SEC CIK
- 1335105 · filings on EDGAR ↗
- Name on the registration
- LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Former names
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (2006–2026); SRKP 7 INC (2005–2006)
- Registration
- Form S-1, first filed 2020-09-03, last 2025-07-10; 4 initial registrations, 8 amendments
- Outcome
- Final prospectus filed 2020-11-27; declared effective 2020-11-24; withdrawal requested 2025-02-10
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 433 PLAZA REAL, SUITE 275, Boca Raton, FL 33432
- EIN
- 20-2903526
- Ticker
- NMAD (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- NOMAD POWER SOLUTIONS, INC. on the corporate pages
Offering terms
- Final price
- $4.75 per share (424B4 filed 2020-11-27)
- Shares sold
- 1,200,000
- Gross proceeds
- $5,700,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LIXT
- Lead underwriters
- WallachBeth Capital
- Syndicate
- Capital, Inc; of Contents
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: LIXTE BIOTECHNOLOGY HOLDINGS, INC. EXACT (CIK (EXACT))
- SEC filer: LIXTE BIOTECHNOLOGY HOLDINGS, INC. EXACT (CIK (EXACT))
Filings 21
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2020-09-03 | S-1 | S-1 (registration) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-20-017243 ↗ |
| 2020-10-13 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-20-019304 ↗ |
| 2020-11-02 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-20-020295 ↗ |
| 2020-11-16 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-20-021457 ↗ |
| 2020-11-24 | EFFECT | EFFECT (declared effective) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 9999999995-20-003294 ↗ |
| 2020-11-27 | 424B4 | 424B4 (final prospectus) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-20-022631 ↗ |
| 2021-02-05 | EFFECT | EFFECT (declared effective) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 9999999995-21-000473 ↗ |
| 2023-08-21 | EFFECT | EFFECT (declared effective) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 9999999995-23-002458 ↗ |
| 2024-05-02 | EFFECT | EFFECT (declared effective) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 9999999995-24-001361 ↗ |
| 2024-10-23 | S-1 | S-1 (registration) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-24-042114 ↗ |
| 2024-11-01 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-24-043388 ↗ |
| 2024-11-05 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-24-043589 ↗ |
| 2025-02-10 | RW | RW (withdrawal request) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001493152-25-005502 ↗ |
| 2025-04-04 | S-1 | S-1 (registration) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001641172-25-002751 ↗ |
| 2025-04-09 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001641172-25-003403 ↗ |
| 2025-04-10 | EFFECT | EFFECT (declared effective) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 9999999995-25-001075 ↗ |
| 2025-04-11 | 424B4 | 424B4 (final prospectus) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001641172-25-003854 ↗ |
| 2025-06-18 | S-1 | S-1 (registration) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001641172-25-015482 ↗ |
| 2025-06-24 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001641172-25-016163 ↗ |
| 2025-07-10 | S-1/A | S-1/A (amendment) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 0001641172-25-018615 ↗ |
| 2025-07-15 | EFFECT | EFFECT (declared effective) | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | 9999999995-25-002256 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-11-16 | S-1/A | registration statement | $4.75 | 1,500,000 | $7,125,000 | OTCQB LIXT | 3 | primary document; price table, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2020-11-27 | 424B4 | final prospectus | $4.75 | 1,200,000 | $5,700,000 | Nasdaq LIXT | 3 | primary document; price table, shares headline, proceeds computed, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| SCHWARTZBERG DEBBIE | TenPercentOwner | 3 | 2006–2014 | ||
| Kovach John S | Director,Officer; Director,Officer,TenPercentOwner | Pres., CFO & Secty; President; President and CEO | 5 | 2006–2022 | |
| Palmedo Philip F | Director | 7 | 2006–2022 | ||
| CARTER STEPHEN K | Director | 1 | 2007 | ||
| Sorensen Mel | Director | 1 | 2008 | ||
| Schwartzberg Gil | Director,TenPercentOwner; TenPercentOwner | 8 | 2010–2022 | ||
| Royds Robert B. | Director | 1 | 2011 | ||
| Riggs Arthur | TenPercentOwner | 4 | 2014–2018 | ||
| Riggs Jane Merrill | TenPercentOwner | 4 | 2014–2018 | ||
| FORMAN ERIC | Officer; Officer,TenPercentOwner; TenPercentOwner | Secretary; Vice President and COO | 12 | 2015–2022 | |
| JOHN & BARBARA KOVACH 2015 TRUST | TenPercentOwner | 1 | 2015 | ||
| Forman Stephen J. | Director | 14 | 2016–2025 | ||
| Ho Hung Tak | TenPercentOwner | 2 | 2017–2020 | ||
| Ho Sze Chun Winson | Director | 2 | 2018–2021 | ||
| Yen Yun | Director | 11 | 2018–2025 | ||
| GREENBERG FAMILY TRUST | TenPercentOwner | 2 | 2018–2020 | ||
| GREENBERG M SUSAN | TenPercentOwner | 2 | 2018–2020 | ||
| GREENBERG ROBERT | TenPercentOwner | 2 | 2018–2020 | ||
| WEINGARTEN ROBERT N | Officer | Vice President and CFO | 2 | 2020–2022 | |
| Brown Regina | Director | 10 | 2021–2025 | ||
| KRINSKY GLENN | TenPercentOwner | 1 | 2022 | ||
| van der Baan Bastiaan Jeroen | Director; Director,Officer | President and CEO; President, CEO & Vice Chairman | 8 | 2022–2023 | |
| Bernards Rene | Director | 11 | 2022–2025 | ||
| Miser James | Officer | Chief Medical Officer | 2 | 2022 | |
| Schellens Johannes Henricus Matthias | Officer | Chief Medical Officer | 1 | 2024 | |
| Pursglove Geordan Garrett | Director,Officer | CEO and Chairman of the Board | 4 | 2025–2026 | |
| Holloway Michael Andrew | Director | 4 | 2025–2026 | ||
| Sawyer Jason David | Director | 4 | 2025–2026 | ||
| Felix Lourdes | Director | 4 | 2025–2026 | ||
| Stazzone Peter | Officer | Chief Financial Officer | 4 | 2025–2026 | |
| Primus Guy Warren | Director | 4 | 2025–2026 | ||
| Porter Stuart D | Director | 2 | 2026 | ||
| Travaglini John Francis | Director | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2023-08-01 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Biotechnology | $3,500,000 | $3,500,000 | 1 | 1 |
| 2018-12-12 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Biotechnology | $4,500,000 | $4,500,000 | 15 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | LIXTE BIOTECHNOLOGY HOLDINGS, INC. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- GENEREX BIOTECHNOLOGY CORP FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- Alaunos Therapeutics, Inc. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- ACCENTIA BIOPHARMACEUTICALS INC FL
- CATALYST PHARMACEUTICALS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health